3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546
Status:
Recruiting
Trial end date:
2021-12-23
Target enrollment:
Participant gender:
Summary
A 3-part Study to Assess Safety, Tolerability, PK and PD of Single (Part 1) and Multiple
(Part 2) Ascending Doses of EXS21546, and to Evaluate the Relative Bioavailability of a Solid
Dose Formulation Compared to a Powder for Oral Suspension (Part 3), in Healthy Male Subjects.